MONTREAL--(BUSINESS WIRE)--Angiochem, Inc., a clinical stage biotechnology company, announced today that preclinical and clinical data demonstrating the broad applicability of its Engineered Peptide Compounds (EPiC) technology to physiologically cross the blood brain barrier (BBB), were presented in a panel at the 6th Annual Peptide Therapeutics Foundation Symposium, October 21, 2011, at the Salk Institute in La Jolla, CA. These data demonstrated that by targeting the lipoprotein receptor-related protein (LRP-1), which is highly expressed on the surface of the BBB, Angiochem’s proprietary EPiC technology enables the creation of breakthrough drugs that physiologically crosses the BBB for the treatment of brain and brain-related diseases such as cancer, pain, diabetes/obesity and Parkinson’s disease. Importantly, this data demonstrated that the EPiC technology is broadly applicable to small molecules, peptides, proteins and biologics.